Search

More money than sense

Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.

Biotech hit by credit crunch

As stock markets turn their backs on the high-risk sectors, France Biotech’s annual survey reveals the depths to which investment has fallen.